Emerald Advisers LLC raised its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 14.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,908,795 shares of the medical research company’s stock after buying an additional 236,965 shares during the quarter. NeoGenomics comprises about 1.2% of Emerald Advisers LLC’s investment portfolio, making the stock its 27th biggest position. Emerald Advisers LLC owned about 2.04% of NeoGenomics worth $24,070,000 as of its most recent filing with the SEC.
A number of other large investors also recently made changes to their positions in NEO. BlackRock Inc. boosted its holdings in shares of NeoGenomics by 4.7% during the second quarter. BlackRock Inc. now owns 4,149,329 shares of the medical research company’s stock worth $54,397,000 after purchasing an additional 184,386 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of NeoGenomics by 28.2% during the second quarter. Dimensional Fund Advisors LP now owns 752,853 shares of the medical research company’s stock worth $9,870,000 after purchasing an additional 165,451 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of NeoGenomics during the second quarter worth $171,000. Northern Trust Corp boosted its holdings in shares of NeoGenomics by 2.2% during the second quarter. Northern Trust Corp now owns 998,807 shares of the medical research company’s stock worth $13,094,000 after purchasing an additional 21,293 shares during the last quarter. Finally, Strs Ohio boosted its holdings in shares of NeoGenomics by 13.2% during the third quarter. Strs Ohio now owns 300,000 shares of the medical research company’s stock worth $4,605,000 after purchasing an additional 35,000 shares during the last quarter. Hedge funds and other institutional investors own 82.57% of the company’s stock.
NASDAQ:NEO opened at $16.52 on Thursday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 3.98 and a current ratio of 4.13. NeoGenomics, Inc. has a 12 month low of $7.08 and a 12 month high of $19.04. The stock has a market capitalization of $1.55 billion, a price-to-earnings ratio of 275.00 and a beta of 0.43.
In other NeoGenomics news, VP Jennifer Balliet sold 68,333 shares of the firm’s stock in a transaction dated Monday, November 12th. The stock was sold at an average price of $16.89, for a total value of $1,154,144.37. Following the transaction, the vice president now directly owns 55,000 shares of the company’s stock, valued at $928,950. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Kevin C. Johnson acquired 26,000 shares of the business’s stock in a transaction on Friday, December 21st. The stock was bought at an average cost of $11.60 per share, for a total transaction of $301,600.00. Following the completion of the transaction, the director now directly owns 103,866 shares of the company’s stock, valued at $1,204,845.60. The disclosure for this purchase can be found here. Insiders sold 15,829,788 shares of company stock worth $213,793,738 over the last three months. 12.20% of the stock is currently owned by corporate insiders.
NEO has been the topic of several research reports. Benchmark set a $22.00 target price on NeoGenomics and gave the stock a “buy” rating in a research report on Thursday, November 1st. Craig Hallum increased their target price on NeoGenomics from $17.00 to $22.00 and gave the stock a “buy” rating in a research report on Wednesday, October 31st. Raymond James increased their target price on NeoGenomics from $16.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, October 31st. Zacks Investment Research raised NeoGenomics from a “hold” rating to a “strong-buy” rating and set a $21.00 target price on the stock in a research report on Saturday, November 3rd. Finally, BidaskClub raised NeoGenomics from a “hold” rating to a “buy” rating in a research report on Tuesday. One research analyst has rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $19.33.
NeoGenomics Company Profile
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories.
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.